Retraction: Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist (PLoS ONE (2013) 8: 12 (e83271) DOI: 10.1371/journal.pone.0083271);Antidepressant-like activity of YL-0919: A novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Chen, Hong Xia ^a   Jin, Zeng Liang ^a,b   Zhang, Li Ming ^a   Xue, Rui ^a   Xu, Xiao Dan ^a   Zhao, Nan ^a   Qiu, Zhi Kun ^a   Wang, Xian Wang ^a,c   Zhang, You Zhi ^a   Yang, Ri Fang ^a   Li, Yun Feng ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLIC AMP; FLUOXETINE; FORSKOLIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; YL 0919;

ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIORAL SCIENCE; BINDING AFFINITY; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DEPRESSION; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EATING; FORCED SWIM TEST; HUMAN; HUMAN CELL; IMMOBILITY; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; RAT; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL TRANSPORT; CYCLIC AMP; DRUG DISCOVERY; FEEDING BEHAVIOR; MALE; MICE; PIPERIDINES; PYRIDONES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84893341634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0304643     Document Type: Erratum

References (57)

1. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry184: 386-392.
2. Mathers CD, Loncar D (2006) Projection of global mortality and burden of disease from 2002 to 2030. Plos Med 3: e442.
3. Nemeroff CB (1998) Psychopharmacology of affective disorders in the 21st century. Biol Psychiatry 44: 517-525.
4. Schloss P, Williams DC (1998) The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 12: 115-1121.
5. Iversen L (2000) Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 5: 357-362.
6. Beasley Jr CM, Holman SL, Potvin JH (1993) Fluoxetine comparedwith imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 5: 199-207.
7. Cookson J (1993) Side-effects of antidepressants. Br J Psychiatry Supp: 20-24.
8. Pinder RM, Wieringa JH (1993) Third-generation antidepressants. Med Res Rev 13: 259-325.
9. Goldstein BJ, Goodnick PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12: S55-87.
10. Newman-Tancredi A, Chaput C, Gavaudan S, Verriele L, Millan MJ (1998) Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology 18: 395-398.
11. Rabiner EA, Bhagwagar Z, Gunn RN, Cowen PJ, Grasby PM (2004) Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression. Neuropsychopharmacology 29: 1688-1698.
12. Serrats J, Artigas F, Mengod G, Mengod G, Cortes R (2004) An autoradiographic study of the influence of pindolol upon [35S] GTPgammasS binding in rat, guinea pig and human brain. Int J Neuropsychopharmacol 7: 27-34.
13. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217-222.
14. Portella MJ, de Diego-Adelino J, Puigdemont D, Perez-Egea R, Alvarez E, et al.(2009) Pindolol augmentation enhances response outcomes in first depressive episodes. Eur Neuropsychopharmacol 19: 516-519.
15. Sim-Selley LJ, Vogt LJ, Xiao R, Childers SR, Selley DE (2000) Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone. Eur J Pharmacol 389: 147-153.
16. Harvey KV, Balon R (1995) Augmentation with buspirone: a review. Ann Clin Psychiatry 7: 143-147.
17. Fava M (2000) New approaches to the treatment of refractory depression. J Clin Psychiatry 61: 26-32.
18. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, et al. (2006) Medication augmentation after the failure of SSRIs for depression. N Eng J Med 354: 1243-1252.
19. Khan A (2009) Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Invertig Drug 18: 1753-1764.
20. Citrome L (2012) Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant -what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 66: 356-358.
21. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, et al. (2012) The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin 28: 27-39.
22. 1A receptor agonist and serotonin transporter inhibitor. Mil Med Sci 35: 676-680.
23. Czeh B, Perez-cruz C, Fuchs E, Flugge G (2008) Chronic stress-induced cellular changes in the medial prefrontal cortex and their potential clinical implications: Does hemisphere location matter? Behav Brain Res 190: 1-13.
24. Englemen EA, Robertson DW, Thompson DC, Perry KW, Wong DT (1996) Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66: 599-603.
25. Jin YY, Lu Q, Yan ZQ, Gao EJ, Zhao CL, et al. (2010) Visualization of serotonin 1A receptor trafficking in neuron-like PC12 cells. Basic & ClinicalMedicine 30: 487-491.
26. 2+ transient, cAMP production and pacemaker frequency of rabbit sinoatrial node cells. Basic Res Cardilo 105: 73-87.
27. Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, et al. (2012) S32212, a novel serotonin type 2C receptor inverse agonist/α2- adrenoceptor antagonist and potential antidepressant: I. a mechanistic characterization. J Pharmacol Exp Ther 340: 750-764.
28. Cheng CHK Costall B, Naylor RJ, Rudd JA (1993) The effect of 5-HT receptor ligands on the uptake of [3H]-5-HT into rat cortical synaptosomes. Eur J Pharmacol 239: 211-214.
29. -12935 bindingin brain: a radioligand for selective labellingof the dopamine transport complex. J.Neurochem 46: 1272-1276.
30. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85: 367-370.
31. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
32. Dias Elpo Zomkowski A, Oscar Rosa A, Lin J, Santos AR, Calixto JB, et al. (2004) Evidence for serotonin receptor subtypes involvement in agmatine antidepreddant-like effect in the mouse forced swimming test. Brain Res 1023: 253-263.
33. Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressive treat- ments. Eur J Pharmacol 47: 379-391.
34. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93: 358-364.
35. An L, ZhangYZ, Yu NJ, Liu XM, Zhao N, et al. (2008) Role for serotonin in the antidepressant-like effects of a flavonoid extract of Xiaobuxin-Tang. Pharmacol Biochem Behav 89: 572-580.
36. Bekris S, Antoniou K, Daskas S, Papadopoulou-Daifoti Z (2005) Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav Brain Res 161: 45-59.
37. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ (1998) The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 95: 298-302.
38. Andersen J, Kristensen AS, Bang-Andersen B, Stromgaard K (2009) Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun(Camb) 7: 3677-3692.
39. Dutta AK, Ghosh B, Biswas S, Reith ME (2008) D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action. Eur J Pharmacol 89: 73-79.
40. Xue R, Jin ZL, Chen HX, Yuan L, He XH, et al. (2013) Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. Eur Neuropsychopharmacol 23: 728-741.
41. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
42. Schoeffier P, Bobimac I, Boddeke E, Hoyer D (1997) Inhibition of cAMP accumulation via recombinant human serotonin 5-HT1A receptors:Considerations on receptor effector coupling across systems. Neuropharmacology 36: 429-437.
43. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
44. Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci. Biobehav Rev 19: 377-395.
45. Kwon S, Lee B, Kim M, Lee H, Park H, et al. (2009) Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test. Prog. Neuropsychopharmacol. Biol Psychiatry 34: 265-270.
46. Lucki I, Singh A, Kreiss DS (1994) Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 18:85-95.
47. Mayorga AJ, Dalvi A, Page ME, Zimov-Levinson S, Hen R (2001) Antidepressant-like behavioral effects in 5-HT1A and 5-HT1B receptor mutant mice. J Pharmacol Exp Ther 298: 1101-1107.
48. Blier P, de Montigny C (1990) Differential effects of gepirone on presynaptic and postsynaptic serotonin receptors: single-cell recording studies. J Clin Psychopharmacol 10: 13S-20S.
49. Davidson C, Stamford JA (1995) Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114: 1107-1109.
50. Papp M, Moryl E, Willner P (1996) Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296: 129-136.
51. Bondi CO, Rodriguez G., Gould G.G., Frazer A, Morilak DA (2008) Chronic unpredictable stress induces a cognitive deficit and anxiety- like behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharmacology 33: 320-331.
52. + ATPase activity is reduced in amygdale of rats with chronic stress-induced anxiety-like behavior. Neurochem Res 35: 1787-1795.
53. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, et al. (2002) Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1- piperazi-nyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist. J Pharmacol Exp 302: 1220-1227.
54. Guay DR (2012) Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder. Consult Pharm 27: 857-867.
55. Tordera RM, Monge A, Del Rio J, Lasheras B (2002) Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. European J Pharmacology 44: 63-71.
56. Romero L, Celada P, Martin-Ruiz R, Diaz-Mataix L, Mourelle M, et al. (2003) Modulation of Serotonergic Function in Rat Brain by VN2222, a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist. Neuropsychopharmacology 28: 445-456.
57. Cruz MP (2012) Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake inhibitor For the Treatment of Major Depressive Disorder. PT 37: 28-31.